A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Omega-3-Polyunsaturated Fatty Acids in Subjects With SLE.
Phase of Trial: Phase IV
Latest Information Update: 20 Nov 2016
At a glance
- Drugs Omega-3-acid ethyl esters (Primary)
- Indications Coronary artery disease; Dyslipidaemias; Systemic lupus erythematosus
- Focus Biomarker; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 27 Jun 2012 Actual patient number changed from 85 to 106 as reported by ClinicalTrials.gov.
- 23 Nov 2011 Status changed from active, no longer recruiting to completed.